Cited 2 times in
Cyclosporine Sparing Effect of Enteric-Coated Mycophenolate Sodium in De Novo Kidney Transplantation
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김명수 | - |
dc.date.accessioned | 2017-11-02T08:08:26Z | - |
dc.date.available | 2017-11-02T08:08:26Z | - |
dc.date.issued | 2017 | - |
dc.identifier.issn | 0513-5796 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/154124 | - |
dc.description.abstract | PURPOSE: The increased tolerability of enteric-coated mycophenolate sodium (EC-MPS), compared to mycophenolate mofetil, among kidney transplant recipients has the potential to facilitate cyclosporine (CsA) minimization. Therefore, a prospective trial to determine the optimum EC-MPS dose in CsA-based immunosuppression regimens is necessary. MATERIALS AND METHODS: A comparative, parallel, randomized, open-label study was performed for 140 patients from four centers to compare the efficacy and tolerability of low dose CsA with standard dose EC-MPS (the investigational group) versus standard dose CsA with low dose EC-MPS (the control group) for six months in de novo kidney transplant recipients. Graft function, the incidence of efficacy failure [biopsy-confirmed acute rejection (BCAR), death, graft loss, loss to follow-up], and adverse events were compared. RESULTS: The mean estimated glomerular filtration rate (eGFR) of the investigational group at six months post-transplantation was non-inferior to that of the control group (confidence interval between 57.3 mL/min/1.73m² and 67.4 mL/min/1.73 m², p<0.001). One graft loss was reported in the control group, and no patient deaths were reported in either group. The incidence of BCAR of the investigational group was 8.7%, compared to 18.8% in the control group (p=0.137), during the study period. There were no significant differences (p>0.05) in the incidence of discontinuations and serious adverse events (SAE) between the groups. CONCLUSION: CsA minimization using a standard dose of EC-MPS kept the incidence of acute rejection and additional risks as low as conventional immunosuppression and provided therapeutic equivalence in terms of renal graft function and safety issues. | - |
dc.description.statementOfResponsibility | open | - |
dc.language | English | - |
dc.publisher | Yonsei University | - |
dc.relation.isPartOf | YONSEI MEDICAL JOURNAL | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Adult | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Cyclosporine/administration & dosage* | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Graft Rejection/prevention & control* | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Immunosuppressive Agents/administration & dosage* | - |
dc.subject.MESH | Incidence | - |
dc.subject.MESH | Kidney Transplantation | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Mycophenolic Acid/administration & dosage* | - |
dc.subject.MESH | Prospective Studies | - |
dc.subject.MESH | Tablets, Enteric-Coated | - |
dc.subject.MESH | Time Factors | - |
dc.title | Cyclosporine Sparing Effect of Enteric-Coated Mycophenolate Sodium in De Novo Kidney Transplantation | - |
dc.type | Article | - |
dc.publisher.location | Korea (South) | - |
dc.contributor.college | College of Medicine | - |
dc.contributor.department | Dept. of Surgery | - |
dc.contributor.googleauthor | Su Hyung Lee | - |
dc.contributor.googleauthor | Jae Berm Park | - |
dc.contributor.googleauthor | Chang-Kwon Oh | - |
dc.contributor.googleauthor | Myoung Soo Kim | - |
dc.contributor.googleauthor | Sung Joo Kim | - |
dc.contributor.googleauthor | Jongwon Ha | - |
dc.identifier.doi | 10.3349/ymj.2017.58.1.217 | - |
dc.contributor.localId | A00424 | - |
dc.relation.journalcode | J02813 | - |
dc.identifier.eissn | 1976-2437 | - |
dc.identifier.pmid | 27873516 | - |
dc.subject.keyword | Enteric-coated mycophenolate sodium | - |
dc.subject.keyword | cyclosporine | - |
dc.subject.keyword | immunosuppression | - |
dc.contributor.alternativeName | Kim, Myoung Soo | - |
dc.contributor.affiliatedAuthor | Kim, Myoung Soo | - |
dc.citation.title | Yonsei Medical Journal | - |
dc.citation.volume | 58 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 217 | - |
dc.citation.endPage | 225 | - |
dc.identifier.bibliographicCitation | YONSEI MEDICAL JOURNAL, Vol.58(1) : 217-225, 2017 | - |
dc.date.modified | 2017-11-01 | - |
dc.identifier.rimsid | 41623 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.